carbostyril has been researched along with Allergic Encephalomyelitis in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.17) | 18.2507 |
| 2000's | 4 (16.67) | 29.6817 |
| 2010's | 17 (70.83) | 24.3611 |
| 2020's | 2 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Alves de Lima, K; Borucki, DM; Chao, CC; Kaye, J; Kenison, JE; Li, Z; Quintana, FJ; Rothhammer, V; Takenaka, MC; Tjon, E | 1 |
| Farinas, MF; Jeffers, M; Kakuk-Atkins, L; Kraus, EE; Lovett-Racke, AE; Yang, Y | 1 |
| Bullitta, S; Centonze, D; De Vito, F; Fresegna, D; Gentile, A; Mandolesi, G; Musella, A; Rizzo, FR | 1 |
| Ayzenberg, I; Dick, HB; Faissner, S; Gold, R; Joachim, SC; Kleiter, I; Kühn, S; Pedreiturria, X; Petrikowski, L; Reinehr, S; Stute, G; Wilmes, AT | 1 |
| Avendaño-Guzmán, E; Bernhardt, G; Brück, W; Dreyer, C; Harden, M; Nessler, S; Ott, M; Schön, M; Schön, MP; Stadelmann, C; Strauss, J; Ullrich, E; Wegner, C | 1 |
| Furlan, R; Hubo, M; Jolivel, V; Jonuleit, H; Klebow, S; Kraus, SH; Luessi, F; Masri, J; Paterka, M; Poisa-Beiro, L; Siffrin, V; Tumani, H; Waisman, A; Yogev, N; Zipp, F | 1 |
| Schulze-Topphoff, U; Varrin-Doyer, M; Zamvil, SS | 1 |
| Hainke, U; Thomas, K; Ziemssen, T | 1 |
| Amit-Romach, E; Ator, MA; Birnberg, T; Caballero, IS; Grossman, I; Hayden, MR; Hingaly, T; Kashi, R; Kaye, J; Knappertz, V; Laifenfeld, D; Laufer, R; Marantz, Y; Orbach, A; Piryatinsky, V; Raymond, E; Rubinstein, E; Shinar, D; Towfic, F | 1 |
| Alvarez, JI; Eckert, N; Flügel, A; Hayardeny, L; Kebir, H; Litke, T; Lodygin, D; Lühder, F; Odoardi, F; Prat, A; Sonneck, M; Sorani, E; Winchenbach, J | 1 |
| Alon, R; Brück, W; Feigelson, S; Hayardeny, L; Pförtner, R; Raymond, E; Stadelmann, C; Timan, B; Wegner, C | 1 |
| Fontoura, P; Garren, H | 1 |
| Brück, W; Wegner, C | 1 |
| Comi, G; Conrad, R; Ellrichmann, G; Gold, R; Hayardeny, L; Lee, DH; Linker, RA; Peruga, I; Seubert, S; Thöne, J; Wiese, S | 1 |
| Molnarfi, N; Nelson, PA; Sagan, SA; Schulze-Topphoff, U; Shetty, A; Sobel, RA; Varrin-Doyer, M; Zamvil, SS | 1 |
| Brück, W; Zamvil, SS | 1 |
| Aharoni, R; Arnon, R; Eilam, R; Hayardeny, L; Saada, R; Sela, M | 1 |
| Mack, M; Mishra, MK; Silva, C; Wang, J; Yong, VW | 1 |
| Barbieri, F; Bergamaschi, A; Brambilla, E; Centonze, D; Comi, G; De Chiara, V; Finardi, A; Hayardeny, L; Martino, G; Motta, C; Rossi, S; Ruffini, F; Studer, V | 1 |
| Aström, M; Brodin, T; Brunmark, C; Hedlund, G; Ohlsson, L; Runström, A; Sparre, B | 1 |
| Abramo, L; Andersson, G; Björk, A; Fex, T; Fristedt, T; Fritzson, I; Hedlund, G; Jansson, K; Jönsson, S; Pekarski, O; Runström, A; Sandin, H; Thuvesson, I | 1 |
| Hedlund, G; Link, H; Xiao, BG; Xu, LY; Yang, JS | 1 |
| Axelsson, B; Leanderson, T; Ohlsson, L; Runström, A | 1 |
| Abramsky, O; Brenner, T; Levi-Schaffer, F; Riesel, N; Soffer, D | 1 |
4 review(s) available for carbostyril and Allergic Encephalomyelitis
| Article | Year |
|---|---|
Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis.
Topics: Administration, Oral; Animals; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Humans; Immunologic Factors; Multiple Sclerosis; Quinolones | 2014 |
Laquinimod in the treatment of relapsing remitting multiple sclerosis.
Topics: Administration, Oral; Animals; Disease Models, Animal; Disease Progression; Encephalomyelitis, Autoimmune, Experimental; Humans; Immunologic Factors; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Neuritis, Autoimmune, Experimental; Quinolones | 2016 |
Multiple sclerosis therapies: molecular mechanisms and future.
Topics: Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Cladribine; Crotonates; Daclizumab; Dimethyl Fumarate; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunoglobulin G; Immunosuppressive Agents; Immunotherapy; Mice; Multiple Sclerosis; Myelin Basic Protein; Nitriles; Peptide Fragments; Propylene Glycols; Quinolones; Rituximab; Sphingosine; Toluidines; Vaccines, DNA | 2010 |
Laquinimod, a once-daily oral drug in development for the treatment of relapsing-remitting multiple sclerosis.
Topics: Administration, Oral; Animals; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Encephalomyelitis, Autoimmune, Experimental; Humans; Mice; Models, Animal; Multiple Sclerosis, Relapsing-Remitting; Quinolones | 2012 |
20 other study(ies) available for carbostyril and Allergic Encephalomyelitis
| Article | Year |
|---|---|
Aryl Hydrocarbon Receptor Activation in Astrocytes by Laquinimod Ameliorates Autoimmune Inflammation in the CNS.
Topics: Animals; Astrocytes; Basic Helix-Loop-Helix Transcription Factors; Encephalomyelitis, Autoimmune, Experimental; Female; Mice; Mice, Inbred C57BL; Mice, Knockout; Quinolones; Receptors, Aryl Hydrocarbon | 2021 |
Regulation of autoreactive CD4 T cells by FoxO1 signaling in CNS autoimmunity.
Topics: Adult; Animals; Autoimmunity; CD4-Positive T-Lymphocytes; Encephalomyelitis, Autoimmune, Experimental; Female; Forkhead Box Protein O1; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Middle Aged; Multiple Sclerosis; Quinolones | 2021 |
Laquinimod ameliorates excitotoxic damage by regulating glutamate re-uptake.
Topics: Animals; Anti-Inflammatory Agents; Cerebellum; Encephalomyelitis, Autoimmune, Experimental; Excitatory Amino Acid Transporter 1; Excitatory Amino Acid Transporter 2; Female; Glutamic Acid; Infusions, Intraventricular; Mice; Mice, Inbred C57BL; Organ Culture Techniques; Quinolones; Random Allocation | 2018 |
Laquinimod protects the optic nerve and retina in an experimental autoimmune encephalomyelitis model.
Topics: Animals; Antigens, Differentiation; Calcium-Binding Proteins; Disease Models, Animal; Dose-Response Relationship, Drug; Electroretinography; Encephalomyelitis, Autoimmune, Experimental; Gene Expression Regulation; Mice; Mice, Inbred C57BL; Microfilament Proteins; Myelin Basic Protein; Myelin-Oligodendrocyte Glycoprotein; Nerve Tissue Proteins; Optic Nerve; Peptide Fragments; Phagocytes; Quinolones; Retina; RNA, Messenger | 2018 |
Laquinimod, a prototypic quinoline-3-carboxamide and aryl hydrocarbon receptor agonist, utilizes a CD155-mediated natural killer/dendritic cell interaction to suppress CNS autoimmunity.
Topics: Animals; Antigens, Differentiation, T-Lymphocyte; Autoimmunity; Dendritic Cells; Encephalomyelitis, Autoimmune, Experimental; Humans; Immunologic Surveillance; Killer Cells, Natural; Lymphocyte Activation; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Mice, Transgenic; Quinolines; Quinolones; Receptors, Aryl Hydrocarbon; Receptors, Virus | 2019 |
Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis.
Topics: Animals; CD4-Positive T-Lymphocytes; Dendritic Cells; Encephalomyelitis, Autoimmune, Experimental; Female; Humans; Mice; Mice, Inbred C57BL; Multiple Sclerosis, Relapsing-Remitting; NF-kappa B; Quinolones | 2013 |
Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor.
Topics: Animals; Cytochrome P-450 CYP1A1; Encephalomyelitis, Autoimmune, Experimental; Female; Gene Deletion; Gene Expression; Gene Expression Profiling; Gene Expression Regulation; Hepatocytes; Humans; Immune System; Mice; Mice, Knockout; Quinolones; Receptors, Aryl Hydrocarbon; T-Lymphocytes; Transcriptome | 2016 |
Laquinimod enhances central nervous system barrier functions.
Topics: Adult; Animals; Blood-Brain Barrier; Capillary Permeability; Cells, Cultured; Encephalomyelitis, Autoimmune, Experimental; Endothelial Cells; Female; Humans; Lymphocytes; Male; Mice, Inbred C57BL; Mice, Transgenic; Multiple Sclerosis, Relapsing-Remitting; Neuroprotective Agents; Quinolones; Rats, Inbred Lew; T-Lymphocytes; Young Adult | 2017 |
Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis.
Topics: Animals; Axons; Cell Movement; Demyelinating Diseases; Down-Regulation; Encephalomyelitis, Autoimmune, Experimental; Female; Inflammation Mediators; Interleukin-17; Mice; Mice, Inbred C57BL; Quinolones; T-Lymphocyte Subsets | 2010 |
Insight into the mechanism of laquinimod action.
Topics: Analysis of Variance; Animals; Brain; Brain-Derived Neurotrophic Factor; Cell Movement; Central Nervous System; Clinical Trials, Phase II as Topic; Cytokines; Dose-Response Relationship, Drug; Encephalomyelitis, Autoimmune, Experimental; Gene Expression Regulation; Humans; Immunologic Factors; Interferon-beta; Leukocytes; Mice; Microscopy, Electron, Transmission; Multiple Sclerosis; Quinolones; Rats | 2011 |
Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor.
Topics: Animals; Brain-Derived Neurotrophic Factor; Cytokines; Encephalomyelitis, Autoimmune, Experimental; Enzyme-Linked Immunosorbent Assay; Humans; Mice; Mice, Inbred C57BL; Monocytes; Multiple Sclerosis; Neuroprotective Agents; Quinolones | 2012 |
Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity.
Topics: Administration, Oral; Adoptive Transfer; Animals; Antigen-Presenting Cells; Dendritic Cells; Encephalomyelitis, Autoimmune, Experimental; Female; Immunologic Factors; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Monocytes; Myeloid Cells; Quinolones; T-Lymphocytes; Th1 Cells; Th17 Cells | 2012 |
Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis.
Topics: Animals; Axons; Brain-Derived Neurotrophic Factor; Demyelinating Diseases; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Female; Immunologic Factors; Mice; Mice, Inbred C57BL; Multiple Sclerosis; Neuroprotective Agents; Quinolones; T-Lymphocytes, Regulatory | 2012 |
Kinetics of proinflammatory monocytes in a model of multiple sclerosis and its perturbation by laquinimod.
Topics: Animals; Cell Count; Cell Movement; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Enzyme Activation; Female; Humans; Inflammation; Kinetics; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinases; Monocytes; Multiple Sclerosis; NF-kappa B; Quinolones; Spinal Cord | 2012 |
Laquinimod prevents inflammation-induced synaptic alterations occurring in experimental autoimmune encephalomyelitis.
Topics: Animals; Brain; Encephalomyelitis, Autoimmune, Experimental; Female; Inflammation; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Patch-Clamp Techniques; Quinolones; Synapses | 2013 |
The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis.
Topics: Adjuvants, Immunologic; Animals; Anti-Inflammatory Agents; B-Lymphocytes; Cells, Cultured; Central Nervous System; Chemotaxis, Leukocyte; Dexamethasone; Dose-Response Relationship, Drug; Encephalomyelitis, Autoimmune, Experimental; Female; Hydroxyquinolines; Immunosuppression Therapy; Mice; Mice, Inbred C57BL; Multiple Sclerosis; Neuroimmunomodulation; Quinolones; T-Lymphocytes | 2002 |
Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship.
Topics: Adjuvants, Immunologic; Animals; Autoimmune Diseases; Dogs; Encephalomyelitis, Autoimmune, Experimental; Female; Hydroxyquinolines; Mice; Mice, Inbred C57BL; Quinolones; Structure-Activity Relationship | 2004 |
Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats.
Topics: Animals; Cytokines; Encephalomyelitis, Autoimmune, Experimental; Female; Hydroxyquinolines; Quinolones; Rats; Rats, Inbred Lew; Th1 Cells; Th2 Cells; Transforming Growth Factor beta | 2004 |
Inhibition of the development of chronic experimental autoimmune encephalomyelitis by laquinimod (ABR-215062) in IFN-beta k.o. and wild type mice.
Topics: Animals; Central Nervous System; Chronic Disease; Dose-Response Relationship, Drug; Encephalomyelitis, Autoimmune, Experimental; Immunohistochemistry; Interferon-beta; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Polymerase Chain Reaction; Quinolones | 2006 |
Mast cell activity in experimental allergic encephalomyelitis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; beta-N-Acetylhexosaminidases; Encephalomyelitis, Autoimmune, Experimental; Female; In Vitro Techniques; L-Lactate Dehydrogenase; Mast Cells; Nedocromil; p-Methoxy-N-methylphenethylamine; Quinolones; Rats; Rats, Inbred Lew; Rats, Inbred Strains; Spinal Cord; Thalamus; Time Factors | 1991 |